Kajian Pengembangan Sistem Nanostructured Lipid Carriers (NLC) Pada Terapi Kanker Payudara
DOI:
https://doi.org/10.29313/bcsp.v3i2.8976Keywords:
Agen Sitotoksik, Kanker Payudara, Nanostructured Lipid carriers (NLC)Abstract
Abstrak. Kanker payudara merupakan kanker dengan angka kejadian dan penyebab kematian tertinggi di Indonesia. Salah satu pengobatan kanker payudara adalah dengan kemoterapi menggunakan agen kemoterapi atau agen sitotoksik. Agen sitotoksik merupakan senyawa aktif yang dapat mengganggu pelekatan, mengubah morfologi, mempengaruhi laju pertumbuhan atau menyebabkan kematian pada sel. Maka dari itu dilakukan pengembangan sistem Nanostructured Lipid carriers (NLC) mengandung agen sitotoksik untuk meningkatkan aktivitas sitotoksik dari senyawa aktif pada terapi kanker payudara. Kajian dilakukan dengan Systematics Literature Review (SLR) terhadap artikel yang diperoleh pada database bereputasi yang memenuhi kriteria eksklusi dan inklusi. Hasil kajian menunjukan bahwa agen sitotoksik sudah banyak dikembangkan dalam sistem NLC diantaranya artemether dan docohexaenoic acid (DHA), dexibuprofen, docetaxel, doxorubicin, eucalyptol, imatinib, kurkumin, paclitaxel, quercetin, resveratrol dan tamoxifen. Formulasi sistem NLC menggunakan solid lipid dan likuid lipid yang distabilkan dengan penambahan surfaktan. Pengembangan sistem NLC terbukti dapat meningkatkan aktivitas sitotoksik senyawa aktif dilihat dari penurunan nilai IC50 yang dibandingkan dengan non NLC sebesar 1,25 hingga 24,94 kalinya.
Kata Kunci: Agen Sitotoksik, Kanker Payudara, Nanostructured Lipid carriers (NLC).
Abstract. Breast cancer is a cancer with the highest incidence and cause of death in Indonesia. One of the treatments of breast cancer is chemotherapy using chemotherapeutic agents or cytotoxic agents. Cytotoxic agents are active compounds that can interfere with attachment, change morphology, affect growth rate or cause death in cells. Therefore, the development of a system of Nanostructured Lipid carriers (NLC) containing cytotoxic agents to increase the cytotoxic activity of active compounds in breast cancer therapy. The study was conducted with Systematics Literature Review (SLR) on articles obtained in reputable databases that meet exclusion and inclusion criteria. The results showed that cytotoxic agents have been widely developed in the NLC system including artemether and docohexaenoic acid (DHA), dexibuprofen, docetaxel, doxorubicin, eucalyptol, imatinib, curcumin, paclitaxel, quercetin, resveratrol and tamoxifen. NLC system formulations use solid lipids and liquid lipids stabilized by the addition of surfactants. The development of the NLC system is proven to increase the cytotoxic activity of active compounds seen from the decrease in IC50 value compared to non-NLC by 1.25 to 24.94 times.
Keywords: Cytotoxic Agent, Breast Cancer, Nanostructured Lipid carriers (NLC).
References
[2] Globocan. Cancer Fact Sheet: Breast Cancer-Iacr. France; 2021 Mar.
[3] American Cancer Society. Breast Cancer Facts & Figures 2022-2024. Atlanta: American Cancer Society, Inc; 2022.
[4] Thiruchenthooran V, Świtalska M, Bonilla L, Espina M, García Ml, Wietrzyk J, Et Al. Novel Strategies Against Cancer: Dexibuprofen-Loaded Nanostructured Lipid Carriers. Int J Mol Sci. 2022 Oct 1;23(19).
[5] Garbayo E, Pascual-Gil S, Rodríguez-Nogales C, Saludas L, Estella-Hermoso De Mendoza A, Blanco-Prieto Mj. Nanomedicine And Drug Delivery Systems In Cancer And Regenerative Medicine. Vol. 12, Wiley Interdisciplinary Reviews: Nanomedicine And Nanobiotechnology. Wiley-Blackwell; 2020.
[6] Izham Mnm, Hussin Y, Rahim Nfc, Aziz Mnm, Yeap Sk, Rahman Hs, Et Al. Physicochemical Characterization, Cytotoxic Effect And Toxicity Evaluation Of Nanostructured Lipid Carrier Loaded With Eucalyptol. Bmc Complement Med Ther. 2021 Dec 1;21(1).
[7] Rohmah M, Raharjo S, Hidayat C, Martien R. Formulasi Dan Stabilitas Nanostructured Lipid Carrier Dari Campuran Fraksi Stearin Dan Olein Minyak Kelapa Sawit. J Apl Teknol Pangan. 2019 Feb 28;8(1).
[8] Aryani R, Hidayat Af, Karimah Az. Desain Dan Optimasi Nlc (Nanostructured Lipid Carriers) Ekstrak Etanol Daun Teh Hijau (Camellia Sinensis L. Kuntze) Dengan Variasi Lipid. J Ilm Farm Farmasyifa. 2021 Jan 30;4(1):41–8.
[9] Amalia Fachriani R, Gita Ayu Safitri P, Chasanah U, Dita Mayangsari F. Pengaruh Waktu Pengadukan Terhadap Karakteristik Fisik Nanostructured Lipid Carriers Menggunakan Metode High Shear Homogenization. Maj Farmasetika [Internet]. 2022 Oct 26;8(1):95–103. Available From: Https://Doi.Org/10.24198/Mfarmasetika.V8i1.41860artikelpenelitian
[10] Kamel Ae, Fadel M, Louis D. Curcumin-Loaded Nanostructured Lipid Carriers Prepared Using Peceoltm And Olive Oil In Photodynamic Therapy: Development And Application In Breast Cancer Cell Line. Int J Nanomedicine. 2019;14:5073–85.
[11] Haider M, Abdin Sm, Kamal L, Orive G. Nanostructured Lipid Carriers For Delivery Of Chemotherapeutics: A Review. Vol. 12, Pharmaceutics. Mdpi Ag; 2020.
[12] Sharma A, Baldi A. Nanostructured Lipid Carriers: A Review. J Dev Drugs [Internet]. [2018;7(1):1–12. Available From: Https://Www.Researchgate.Net/Publication/332073718
[13] Duong Va, Nguyen Ttl, Maeng Hj. Preparation Of Solid Lipid Nanoparticles And Nanostructured Lipid Carriers For Drug Delivery And The Effects Of Preparation Parameters Of Solvent Injection Method. Molecules. 2020;25(20):1–36.
[14] Iqbal Ma, Md S, Sahni Jk, Baboota S, Dang S, Ali J. Nanostructured Lipid Carriers System: Recent Advances In Drug Delivery. Vol. 20, Journal Of Drug Targeting. 2012. P. 813–30.
[15] Rizwanullah M, Ahmad J, Amin S. Nanostructured Lipid Carriers: A Novel Platform For Chemotherapeutics. Vol. 13, Current Drug Delivery. 2016.
[16] Subramaniam B, Siddik Zh, Nagoor Nh. Optimization Of Nanostructured Lipid Carriers: Understanding The Types, Designs, And Parameters In The Process Of Formulations. Vol. 22, Journal Of Nanoparticle Research. Springer; 2020.
[17] Tamjidi F, Shahedi M, Varshosaz J, Nasirpour A. Nanostructured Lipid Carriers (Nlc): A Potential Delivery System For Bioactive Food Molecules. Vol. 19, Innovative Food Science And Emerging Technologies. 2013. P. 29–43.
[18] How Cw, Rasedee A, Manickam S, Rosli R. Tamoxifen-Loaded Nanostructured Lipid Carrier As A Drug Delivery System: Characterization, Stability Assessment And Cytotoxicity. Colloids Surfaces B Biointerfaces. 2013 Dec 1;112:393–9.
[19] Makeen Ha, Mohan S, Al-Kasim Ma, Sultan Mh, Albarraq Aa, Ahmed Ra, Et Al. Preparation, Characterization, And Anti-Cancer Activity Of Nanostructured Lipid Carriers Containing Imatinib. Pharmaceutics. 2021 Jul 1;13(7).
[20] Rochman Mf, Darmawan A, Wardhana P. Nanostructured Lipid Carriers System Solid Lipid Poloxamer And Stearic Acid With Liquid Lipid Soybean Oil. J Ilm Medicam. 2022 Mar 29;8(1):1–7.
[21] Aisiyah S, Harjanti R, Nopiyanti V. Pengaruh Panjang Rantai Karbon Lipid Padat Terhadap Karakteristik Nanostructured Lipid Carrier Resveratrol. Jpscr J Pharm Sci Clin Res. 2019 Nov 1;4(2):69.
[22] Lanna Eg, Siqueira Rp, Machado Mgc, De Souza A, Trindade Ic, Branquinho Rt, Et Al. Lipid-Based Nanocarriers Co-Loaded With Artemether And Triglycerides Of Docosahexaenoic Acid: Effects On Human Breast Cancer Cells. Biomed Pharmacother. 2021 Feb 1;134.
[23] Febriani A, Rahmawati Y, Pulmonologi D, Ilmu D, Respirasi K, Kedokteran F, Et Al. Efek Samping Hematologi Akibat Kemoterapi Dan Tatalaksananya. Vol. 5. 2019.
[24] Mcgaw Lj, Elgorashi Ee, Eloff Jn. Cytotoxicity Of African Medicinal Plants Against Normal Animal And Human Cells. In: Toxicological Survey Of African Medicinal Plants. Elsevier Inc.; 2014. P. 181–233.
[25] Marcial Sp De S, Carneiro G, Leite Ea. Lipid-Based Nanoparticles As Drug Delivery System For Paclitaxel In Breast Cancer Treatment. J Nanoparticle Res. 2017 Oct 1;19(10):1–11.
